Partial epigenetic reprogramming

01Overview and value chain#

Markers EC: ATMP Regulation (EC No 1394/2007) | OECD: Biotech-health | Regulator: FDA (USA), EMA (European Union), NMPA (China)

Partial epigenetic reprogramming transiently expresses Yamanaka transcription factors (Oct4, Sox2, Klf4 — OSK) to reverse epigenetic markers of cellular aging, stopping before a cell loses its original identity, rather than fully reprogramming it back to a pluripotent state. Life Biosciences’ lead candidate ER-100 (AAV2-OSK) is in Phase I clinical trials for optic neuropathies, described as the first-ever epigenetic restoration candidate approved for clinical trials — a world-first therapy to make cells young again given to a person — with a related OSK gene therapy also approved for glaucoma eye trials. Altos Labs, one of the best-funded longevity startups, continued advancing its partial-reprogramming rejuvenation platform through 2026, following the in vivo partial cellular reprogramming approach associated with its Belmonte-linked research. Retro Biosciences, backed by Sam Altman, closed a funding round at a $1.8 billion valuation in May 2026, working on iPSC-derived, AAV and small-molecule therapies with the help of AI models to accelerate its life-science research. NewLimit reported restoring “youthful function” to liver and immune cells through epigenetic reprogramming payload discovery, and published a January/February 2026 progress update on its AI-driven payload-discovery systems. In the UK, Shift Bioscience identified a novel single-gene target (SB000) for safer cellular rejuvenation, reversing cellular ageing as measured by DNA methylation clocks without loss of cellular identity or signs of pluripotency. In China, JingTong Life closed a tens-of-millions-yuan angel funding round for its aging-reversal research, led by CAS Star (中科创星) and Saizhi Bole, reported across multiple Chinese outlets in 2026.

The key directions of partial epigenetic reprogramming are:

1. OSK gene therapy reprogramming (OSK Gene Therapy Reprogramming): AAV-delivered Yamanaka-factor gene therapy dosed directly in patients, the field’s first clinical-stage approach — Life Biosciences’ ER-100 (AAV2-OSK).
2. Epigenetic payload discovery (Epigenetic Payload Discovery): AI- and screening-driven discovery of reprogramming payloads that restore youthful cell function in specific tissues — NewLimit’s liver and immune cell programs, Altos Labs’ broader rejuvenation platform.
3. Safer rejuvenation gene targets (Safer Rejuvenation Gene Targets): identifying minimal, single-gene interventions that reverse epigenetic-clock aging markers without the cancer or identity-loss risk of full Yamanaka-factor reprogramming — Shift Bioscience’s SB000.
4. Cellular age-reversal platforms (Cellular Age-Reversal Platforms): broad, well-funded platforms combining reprogramming with other longevity modalities (iPSC-derived, AAV, small-molecule therapies) — Retro Biosciences, and China’s JingTong Life at an earlier funding stage.

Sectoral value chain#

[reprogramming factor/payload discovery] ──> [preclinical safety/efficacy validation] ──> [regulatory clearance for clinical trial (FDA/EMA/NMPA)]
                                                    │
                                       (clinical dosing/delivery)
                                                    │
                                                    ▼
[indication/tissue expansion] <─── [clinical outcome data generation] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• OSK gene therapy delivery (OSK Gene Therapy Reprogramming): AAV vectors delivering Oct4/Sox2/Klf4 transcription factors directly to target tissue, dosed transiently to avoid full dedifferentiation.
• AI-driven payload discovery (Epigenetic Payload Discovery): machine-learning systems screening for reprogramming payloads that restore tissue-specific youthful gene-expression patterns.
• Epigenetic clock validation (Safer Rejuvenation Gene Targets): DNA methylation-based biomarkers (Horvath clocks) used to measure and validate cellular age reversal.

02US#

The US hosts the world’s best-funded partial reprogramming companies, spanning the field’s first clinical-stage gene therapy and multiple AI-driven discovery platforms.

Life Biosciences, Altos Labs, Retro Biosciences, NewLimit, FDA#

• Life Biosciences: its lead candidate ER-100 (AAV2-OSK) is in Phase I clinical trials for optic neuropathies, described as the first-ever epigenetic restoration candidate approved for clinical trials, with a related OSK gene therapy also approved for glaucoma eye trials.
• Altos Labs: one of the best-funded longevity startups, continued advancing its partial-reprogramming rejuvenation platform through 2026.
• Retro Biosciences: backed by Sam Altman, closed a funding round at a $1.8 billion valuation in May 2026, working on iPSC-derived, AAV and small-molecule therapies with the help of AI models.
• NewLimit: reported restoring “youthful function” to liver and immune cells through epigenetic reprogramming payload discovery, publishing a January/February 2026 progress update on its AI-driven discovery systems.
• FDA framework: partial reprogramming gene therapies require FDA IND clearance to begin human dosing, with Life Biosciences’ ER-100 the field’s first candidate to reach that stage.

03CN#

China’s confirmed partial reprogramming activity centers on an early-stage, well-connected startup that closed its first institutional funding round in 2026.

JingTong Life, NMPA#

• JingTong Life (菁童生命): closed a tens-of-millions-yuan angel funding round for its aging-reversal research, led by CAS Star (中科创星) and Saizhi Bole, reported across multiple Chinese outlets in 2026.
• NMPA pathway: partial reprogramming gene therapies would register with NMPA following the standard investigational gene-therapy pathway once a candidate reaches clinical readiness.

04EU#

The UK anchors Europe’s partial reprogramming capacity through a company focused specifically on identifying safer, minimal-intervention rejuvenation targets rather than full Yamanaka-factor gene therapy.

Shift Bioscience, EMA#

• Shift Bioscience (UK): identified a novel single-gene target (SB000) for safer cellular rejuvenation, reversing cellular ageing as measured by DNA methylation clocks in multiple cell types without loss of cellular identity or signs of pluripotency; the company’s near-term clinical product is an antifibrotic siRNA therapeutic for cell rejuvenation, chosen for a more straightforward regulatory path to clinical proof of concept than full reprogramming.
• EMA framework: any clinical-stage reprogramming or rejuvenation gene therapy reaching EU trials would require EMA advanced-therapy medicinal product (ATMP) clearance.

05Leading companies and research institutes#

06Tech stack and innovations#

The stack applies transient transcription-factor expression or targeted single-gene intervention to reverse epigenetic aging markers while preserving a cell’s original functional identity.

1. OSK gene therapy reprogramming (OSK Gene Therapy Reprogramming):
   • Life Biosciences’ ER-100 delivers AAV2-OSK directly to patients, the field’s first candidate to reach human dosing, targeting optic neuropathies and glaucoma-related vision loss.
2. Epigenetic payload discovery (Epigenetic Payload Discovery):
   • NewLimit’s AI-driven discovery systems identify reprogramming payloads that restore youthful gene-expression patterns in liver and immune cells, while Altos Labs pursues a broader rejuvenation platform.
3. Safer rejuvenation gene targets (Safer Rejuvenation Gene Targets):
   • Shift Bioscience’s SB000 single-gene target reverses DNA methylation-clock aging markers without the cancer or identity-loss risk associated with full Yamanaka-factor reprogramming.
4. Broad cellular age-reversal platforms (Cellular Age-Reversal Platforms):
   • Retro Biosciences combines iPSC-derived, AAV and small-molecule modalities with AI-accelerated research, while JingTong Life represents an earlier-stage entrant pursuing the same broad aging-reversal thesis in China.

07Value chains and production pipelines#

Industrial pipeline of a partial reprogramming therapy (FDA IND / EMA ATMP / NMPA)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Reprogramming factor/  │ ───> │ 2. Preclinical safety/    │
│    payload discovery         │      │    efficacy validation      │
└───────────────────────────┘      └───────────────────────────┘
                                                   │
                                                   ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Clinical dosing/        │ <─── │ 3. Regulatory clearance  │
│    delivery                   │      │    for clinical trial       │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Clinical outcome data  │ ───> │ 6. Indication/tissue      │
│                              │      │    expansion                │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Reprogramming factor and payload discovery

Which transcription factors or minimal gene combinations reverse epigenetic aging markers without erasing cell identity are identified, as with Shift Bioscience’s discovery of its single-gene SB000 target versus the full OSK approach used by Life Biosciences.

Stage 2: Preclinical safety and efficacy validation

The payload is tested in animal models for age-reversal efficacy and cancer/identity-loss risk, the validation step behind Shift Bioscience’s demonstration that SB000 reverses methylation-clock aging without pluripotency signs.

Stage 3: Regulatory clearance for clinical trial

FDA IND, EMA or NMPA clearance is obtained to begin human dosing, with Life Biosciences’ ER-100 the field’s first candidate to reach this stage for optic neuropathies.

Stage 4: Clinical dosing and delivery

The reprogramming payload is delivered to patients, typically via AAV gene therapy, as with Life Biosciences’ AAV2-OSK dosing described as the first time cells have been rejuvenated in a living person.

Stage 5: Clinical outcome data generation

Safety, tolerability and age-reversal biomarker data are collected, the evidence base Life Biosciences is generating in its Phase I optic-neuropathy and glaucoma trials.

Stage 6: Indication and tissue expansion

Outcome evidence supports expanding to new tissues or disease indications, the pattern behind NewLimit’s parallel liver and immune-cell programs and the broader multi-modality platforms Altos Labs and Retro Biosciences are building around their initial reprogramming research.